FDA Accepts Biologics License Application for AMG 334 (Erenumab), an Important Regulatory Milestone for Novartis

FDA Accepts Biologics License Application for AMG 334 (Erenumab), an Important Regulatory Milestone for Novartis

Jul 20, 2017
Source URL: https://qa1.novartis.us/news/media-releases/fda-accepts-biologics-license-application-amg-334-erenumab-important-regulatory-milestone-novartis-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/fda-accepts-biologics-license-application-amg-334-erenumab-important-regulatory-milestone-novartis-0